GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CSPC Pharmaceutical Group Ltd (HKSE:01093) » Definitions » EPS without NRI

CSPC Pharmaceutical Group (HKSE:01093) EPS without NRI : HK$0.54 (TTM As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is CSPC Pharmaceutical Group EPS without NRI?

CSPC Pharmaceutical Group's earnings per share without non-recurring items for the three months ended in Dec. 2023 was HK$0.13. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.54.

During the past 12 months, CSPC Pharmaceutical Group's average earnings per share (NRI) Growth Rate was -4.90% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 3.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 14.40% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 23.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for CSPC Pharmaceutical Group's EPS without NRI or its related term are showing as below:

HKSE:01093' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.8   Med: 24.1   Max: 303.7
Current: 3.6

During the past 13 years, CSPC Pharmaceutical Group's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 303.70% per year. The lowest was -60.80% per year. And the median was 24.10% per year.

HKSE:01093's 3-Year EPS without NRI Growth Rate is ranked worse than
60.86% of 833 companies
in the Drug Manufacturers industry
Industry Median: 11.4 vs HKSE:01093: 3.60

CSPC Pharmaceutical Group's EPS (Diluted) for the three months ended in Dec. 2023 was HK$0.13. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.54.

CSPC Pharmaceutical Group's EPS (Basic) for the three months ended in Dec. 2023 was HK$0.13. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.54.


CSPC Pharmaceutical Group EPS without NRI Historical Data

The historical data trend for CSPC Pharmaceutical Group's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSPC Pharmaceutical Group EPS without NRI Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.49 0.57 0.57 0.54

CSPC Pharmaceutical Group Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.14 0.14 0.14 0.13

Competitive Comparison of CSPC Pharmaceutical Group's EPS without NRI

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSPC Pharmaceutical Group's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's PE Ratio without NRI falls into.



CSPC Pharmaceutical Group EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CSPC Pharmaceutical Group  (HKSE:01093) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


CSPC Pharmaceutical Group EPS without NRI Related Terms

Thank you for viewing the detailed overview of CSPC Pharmaceutical Group's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


CSPC Pharmaceutical Group (HKSE:01093) Business Description

Traded in Other Exchanges
Address
No. 226 Huanghe Street, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.

CSPC Pharmaceutical Group (HKSE:01093) Headlines

No Headlines